@FiercePharma: Fresenius Kabi yanks four lots of benztropine mesylate on risk of glass particles, stops distribution to investigate. News | Follow @FiercePharma
@EricPFierce: ICYMI: FDA approves first non-hormonal treatment for hot flashes. Release | Follow @EricPFierce
> Hikma Pharmaceuticals inked a deal to commercialize Theravance's ($THRX) treatment for drug-resistant staph infections, Vibativ, in the Middle East and Africa. Release
> Sanofi ($SNY) won Japanese approval for its new diabetes drug Lyxumia; its application for U.S. approval is still pending. Report
> GlaxoSmithKline ($GSK) moved 150 research projects back to the U.K. to take advantage of the new "patent box" tax rate of 10%. Report
> Fresenius Kabi's U.S. unit recalled four lots of its benztropine mesylate injection on the possibility of glass particles in drug vials and stopped distributing the products pending an investigation. Report
> India's Aurobindo Pharma signed a deal with the Medicines Patent Pool to produce medicines for treating children with HIV. Report
> Pharming agreed to collaborate with a Sinopharm subsidiary on selling the Dutch biotech's angioedema drug Ruconest/Rhucin and developing other treatments. Report
@FierceMedDev: Veracyte nails $28M Series C. Story | Follow @FierceMedDev
@MarkHFierce: There's still time to submit your nomination for this year's FMD Fierce 15. More | Follow @MarkHFierce
@DamianFierce: Thoratec is spending up to $56.5M for Terumo's in-development heart device. News | Follow @DamianFierce
> Malaysia's new device regs poised to heighten the competition. Article
> A drug-free Covidien is now all about devices. Story
> Zyomyx pulls in $12M to advance low-cost HIV Dx to finish line. More
Biotech News
@FierceBiotech: Insmed shares routed on head-to-head antibiotic Phase III results. Story | Follow @FierceBiotech
@JohnCFierce: The FDA's suvorexant decision was expected. I don't see how weak suvo competes with the generics. It'll be an alternative for non-response. | Follow @JohnCFierce
@RyanMFierce: Onyx is following the M&A resistance strategy, which Termeer and more recently Martin have used. More | Follow @RyanMFierce
> FDA scraps Merck's high-dose sleep drug, demands weaker version. Story
> Report: China rounds up GlaxoSmithKline staffers in corruption probe. Article
CRO News
> MMS teams up with Datatrak for eClinical heft. Story
> Want to work with Roche? Prepare for high standards. More
> AstraZeneca taps Sarah Cannon for cancer R&D. Article
Biotech IT News
> Ex-Googlers bring Big Data analytics to oncology. News
> Deloitte turns EHR reservoir into health outcomes tool. Article
> J&J teams up with Mount Sinai on bioinformatics project. Story
> Data secrecy and outdated tech exacerbating drug shortages. More
And Finally... The World Health Organization called for earlier treatment of patients diagnosed with HIV infection; under new guidelines, 26 million patients would need treatment worldwide. Report